MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202521095813 A) filed by Crassula Pharmaceuticals Pvt. Ltd. on October 06, 2025, for A Novel Cationic Phospholipid Vesicular System For Solubility And Bioavailability Enhancement Of Herbal, Nutrient And Mineral Bioactives.
Inventors include Roopesh Gupta; Lavleen Kumar Gupta; and Bhawana Gupta.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: ABSTRACT A NOVEL CATIONIC PHOSPHOLIPID VESICULAR SYSTEM FOR SOLUBILITY AND BIOAVAILABILITY ENHANCEMENT OF HERBAL, NUTRIENT AND MINERAL BIOACTIVES The present invention relates to the QuanticSphere Phytosome Quantum Nano Sphere (PQNS), a cationic phospholipid- based nanovesicular delivery system designed to enhance the bioavailability, stability, and targeted delivery of bioactive agents, including nutraceuticals, phytochemicals, vitamins, and mineral compounds. The PQNS (Phytosome Quantum Nano Sphere) comprises self-assembled spherical vesicles formed from one or more bilayers of cationic phospholipids, which organize spontaneously in aqueous environments due to their amphiphilic nature, creating a structure with a hydrophilic core and a lipophilic bilayer capable of encapsulating both hydrophilic and hydrophobic actives. This architecture protects the ingredients from degradation by gastric acidity, digestive enzymes, and luminal metabolism, significantly enhancing stability and oral bioavailability. The cationic surface charge promotes strong electrostatic interactions with negatively charged cell membranes, facilitating cellular adhesion, membrane fusion, endocytosis, and direct intracellular delivery into the cytoplasm, thereby bypassing lysosomal degradation and improving intracellular bioavailability. The system enables controlled and sustained release of the encapsulated compounds, modulated by bilayer composition, charge, and environmental stimuli such as pH or enzymatic activity, maintaining steady physiological levels and reducing dosing frequency. Surface functionalization allows for targeted delivery to specific tissues or cells. Additionally, the vesicular barrier minimizes direct contact between irritant compounds and the gastrointestinal mucosa, reducing nausea, discomfort, and inflammation. The present invention further includes methods of preparation and uses in nutraceutical, phytochemical and cosmeceutical applications, representing a biocompatible, efficient, and advanced platform for optimized delivery of poorly absorbed and labile bioactives.
Disclaimer: Curated by HT Syndication.
